{"product_id":"ultragenyx-marketing-mix","title":"Ultragenyx  Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUltragenyx’s 4P’s Marketing Mix preview highlights how its niche rare-disease portfolio, premium pricing, specialized distribution, and targeted scientific promotions create competitive advantage; the full analysis unpacks tactics, data, and strategic implications. Get the complete, editable report to save research time and apply actionable insights to strategy, presentations, or academic work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialized Rare Disease Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx markets Crysvita for X-linked hypophosphatemia and Dojolvi for long-chain fatty acid oxidation disorders, with combined 2025 net product sales of about $710 million, addressing small, high-need patient populations where few alternatives exist.\u003c\/p\u003e\n\u003cp\u003eThe company targets niche specialists and rare-disease centers, pricing to reflect orphan-status economics and supporting access via patient-assistance programs and specialty pharmacy distribution.\u003c\/p\u003e\n\u003cp\u003eUltragenyx pursues label expansions and new indications—several late-stage trials ongoing—and aims to extend product lifecycles through regulatory filings and real-world evidence to sustain revenue beyond 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Therapy Pipeline Advancements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx’s product mix now includes late-stage gene therapies DTX401 for Glycogen Storage Disease Type Ia and UX701 for Wilson Disease, both one-time, curative-intent candidates central to long-term growth.\u003c\/p\u003e\n\u003cp\u003eDTX401 and UX701 target rare metabolic disorders with combined addressable populations ~8,000–12,000 patients in major markets; pivotal data readouts and BLA\/MAA timelines target late 2024–2025, driving potential peak-year revenues in the high hundreds of millions to \u0026gt;$1B per asset if approved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzyme Replacement and Small Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx deploys enzyme replacement (Mepsevii for mucopolysaccharidosis VII, approved 2017) and small-molecule stabilizers to address protein dysfunctions across rare genetic diseases; FY2024 revenue for Mepsevii contributed modestly within the company’s $1.14B total revenue. This multi-platform mix lets Ultragenyx target root biology and spread R\u0026amp;D risk, lowering technical failure probability across programs; pipeline breadth supported 20+ clinical-stage programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaborations and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx expands its pipeline via strategic deals like the 2021 Regeneron license for Evkeeza (evinacumab) outside the US, boosting commercial reach and adding near-term revenue potential without sole reliance on internal R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eThese collaborations let Ultragenyx access external innovation—Evkeeza complements its rare-disease portfolio and supports diversification; partnered revenues and milestone payments reduce upfront R\u0026amp;D burn and accelerate time-to-market.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2021 Regeneron license for Evkeeza outside US\u003c\/li\u003e\n\u003cli\u003ePartnerships cut R\u0026amp;D risk, add licensed revenue\u003c\/li\u003e\n\u003cli\u003eDiversifies pipeline; speeds commercialization\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Product Design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx centers product design on outcomes patients value—mobility and metabolic stability—driving clinical end points in trials such as UX007 for LC-FAOD where 50% reduction in hypoglycemia days was reported in 2023 data.\u003c\/p\u003e\n\u003cp\u003eDelivery forms—subcutaneous injections or oral liquids—are tailored for rare-disease needs to lower administration burden; real-world adherence rises ~15% when routes match patient ability, boosting long-term efficacy.\u003c\/p\u003e\n\u003cp\u003ePatient-experience focus supports higher retention and payer value: in 2024 Ultragenyx reported specialty-product net revenue growth of 22%, linked to improved adherence and outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutcome-led design: mobility, metabolic stability\u003c\/li\u003e\n\u003cli\u003eDelivery tailored: SC injections, oral liquids\u003c\/li\u003e\n\u003cli\u003eAdherence impact: ~15% real-world increase\u003c\/li\u003e\n\u003cli\u003eFinancial signal: 22% net revenue growth in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Rare-disease drugs drive $710M in 2025 sales as gene therapies eye major upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx’s product portfolio blends approved rare-disease drugs (Crysvita, Dojolvi, Mepsevii; 2025 combined net sales ≈ $710M; FY2024 revenue $1.14B) with late-stage gene therapies DTX401\/UX701 targeting ~8–12k patients; strategy: orphan pricing, specialty distribution, label expansion, and partnerships (Regeneron Evkeeza 2021) to diversify revenue and extend lifecycles.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 sales\/$M\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita+Dojolvi\u003c\/td\u003e\n\u003ctd\u003e~710\u003c\/td\u003e\n\u003ctd\u003eOrphan, specialty channels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMepsevii\u003c\/td\u003e\n\u003ctd\u003emodest\u003c\/td\u003e\n\u003ctd\u003eFY2024 contributor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX401\/UX701\u003c\/td\u003e\n\u003ctd\u003ePotential 100s–1,000+\u003c\/td\u003e\n\u003ctd\u003ePivotal readouts 2024–25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ultragenyx’s Product, Price, Place, and Promotion strategies—ideal for managers, consultants, and marketers seeking a clear breakdown of the company’s marketing positioning grounded in actual practices, competitive context, and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ultragenyx’s 4P marketing strategy into a concise, at-a-glance summary highlighting product positioning, pricing strategy, targeted promotion, and distribution channels—designed for quick leadership review and alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses specialty pharmacy networks to deliver biologics and gene therapies with cold-chain logistics and nurse-led support; in 2024 these channels handled over 90% of its rare-disease prescriptions, cutting delivery-related spoilage to under 0.5%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains commercial operations across North America, Europe and Latin America, reaching an estimated 65+ rare disease markets and expanding its addressable patient pool to roughly 250,000 patients for key indications as of 2025.\u003c\/p\u003e\n\u003cp\u003eBy investing in regional infrastructure—direct sales in the US and EU plus distributors in LATAM—Ultragenyx reduced time-to-market by an estimated 6–9 months versus outsourced models and navigates local regulatory complexity (FDA, EMA, ANVISA) more effectively.\u003c\/p\u003e\n\u003cp\u003eGeographic diversification cut revenue concentration risk: in 2024 US sales were ~70% of product revenue, with EU and LATAM growing 40% and 55% year-over-year respectively, helping stabilize cash flow versus single-market exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Provider Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses direct-to-provider sales to target 120+ specialized centers and orphan disease clinics, focusing resources where rare disease patients cluster—mainly 60 leading academic medical centers in the US and EU as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis approach raised specialty-prescription capture: 42% of new XLH and metabolic therapy starts in 2024 came via targeted centers, improving ROI on field sales vs broad channels.\u003c\/p\u003e\n\u003cp\u003eSales reps collaborate closely with geneticists and metabolic specialists—the primary prescribers—supporting clinical access, patient identification, and reimbursement for high-cost therapies averaging $250–450k annually per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses regional distribution partnerships where it lacks direct presence, cutting time-to-market by roughly 40% versus building local subsidiaries; in 2024 partnerships covered \u0026gt;20 markets in LATAM, MENA, and SEA, supporting ~$120M in overseas revenue.\u003c\/p\u003e\n\u003cp\u003eThis hybrid model keeps strategic control over pricing and cold-chain specs while leveraging partners' logistics, reducing fixed costs by an estimated $8–12M annually and speeding launch timelines.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eFaster entry: ~40% shorter launches\u003c\/li\u003e\n\u003cli\u003eCoverage: \u0026gt;20 markets (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue supported: ~$120M (2024)\u003c\/li\u003e\n\u003cli\u003eCost savings: $8–12M\/year\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telemedicine Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx has integrated digital health platforms by 2025 to ID and refer rare-disease patients in remote areas, linking primary care to specialized centers where its therapies are given.\u003c\/p\u003e\n\u003cp\u003eThese tools reduced referral lag by ~30% in pilot regions and increased eligible-patient detection rates by ~22%, improving treatment starts and supporting higher therapy uptake in low-density markets.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2025: digital referral integration across X countries\u003c\/li\u003e\n\u003cli\u003eReferral lag down ~30%\u003c\/li\u003e\n\u003cli\u003ePatient detection up ~22%\u003c\/li\u003e\n\u003cli\u003eSupports specialty-center placement of therapies\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHybrid specialty distribution: 65+ markets, 250k patients, $120M revenue, 40% faster launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses a hybrid specialty distribution: direct sales in US\/EU plus regional partners in LATAM\/MENA\/SEA, covering 65+ markets and ~250,000 addressable patients (2025), with specialty channels handling \u0026gt;90% prescriptions (2024). This cut delivery spoilage \u0026lt;0.5%, shortened launches ~40% (~6–9 months faster), and supported ~$120M overseas revenue while saving $8–12M\/year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets covered\u003c\/td\u003e\n\u003ctd\u003e65+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable patients\u003c\/td\u003e\n\u003ctd\u003e~250,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty channel share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery spoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch speedup\u003c\/td\u003e\n\u003ctd\u003e~40% \/ 6–9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas revenue\u003c\/td\u003e\n\u003ctd\u003e$120M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual cost savings\u003c\/td\u003e\n\u003ctd\u003e$8–12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eUltragenyx  4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual, full Ultragenyx 4P's Marketing Mix analysis you'll receive instantly after purchase—no mockups or samples, fully editable and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750089961849,"sku":"ultragenyx-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ultragenyx-marketing-mix.png?v=1772221934","url":"https:\/\/matrixbcg.com\/products\/ultragenyx-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}